



## Musculoskeletal Regenerative Medicine

Guest Editors:

**Dr. Ashim Gupta**

South Texas Orthopaedic  
Research Institute, Laredo, TX,  
USA

**Prof. Dr. Nicola Maffulli**

Deadline for manuscript  
submissions:

**31 August 2024**

### Message from the Guest Editors

Over the last decade, there has been an increasing interest in the use of biologics for regenerative medicine applications. In regenerative medicine, functional tissue is engineered to repair, regenerate, or replace cells, tissues, or organs to restore and/or establish normal function lost from age, disease, damage, or congenital defects. Both autologous and allogenic biologics are currently used in clinical practice. Autologous biologics include platelet-rich plasma, bone marrow aspirate/concentrate, and adipose tissue aspirate. Allogenic biologics include formulations derived from perinatal tissues, including amniotic fluid, amniotic membrane, umbilical cord, and umbilical cord blood. The healing potential of these products is attributed to the presence of stem cells, growth factors, cytokines, hyaluronic acid, and extracellular vesicles, including exosomes.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research

Learning, Spaulding

Rehabilitation Hospital and

Massachusetts General Hospital,

Harvard Medical School, Boston,

MA 02114, USA

2. Department of Epidemiology,

Harvard T.H. Chan School of

Public Health, Boston, MA 02115,

USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPus / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)